Summary of Luminex Corporation (NASDAQ:LMNX) Ratings as of Jun 29, 2018

June 29, 2018 - By Alberto Lyles

Luminex Corporation (NASDAQ:LMNX) Corporate Logo

Luminex Corporation (NASDAQ:LMNX) Ratings Coverage

In total 2 analysts cover Luminex (NASDAQ:LMNX). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. (NASDAQ:LMNX) has 50% bullish analysts. 3 are the (NASDAQ:LMNX)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. In Monday, May 7 report Deutsche Bank upgraded it to “Hold” rating and $2200 target. Listed here are Luminex Corporation (NASDAQ:LMNX) PTs and latest ratings.

07/05/2018 Broker: Deutsche Bank Rating: Hold New Target: $22.0000 Upgrade
08/01/2018 Broker: BTIG Research Rating: Buy New Target: $24.0
05/01/2018 Broker: BTIG Research Rating: Buy New Target: $24 Initiates Coverage On

Ticker’s shares touched $29.21 during the last trading session after 1.14% change.Luminex Corporation has volume of 53,454 shares. Since June 29, 2017 LMNX has risen 33.74% and is uptrending. LMNX outperformed by 21.17% the S&P500.

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide.The firm is valued at $1.30 billion. The companyÂ’s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; Verigene system, an automated multiplex-capable system; and ARIES system, a sample to answer real-time PCR platform.The P/E ratio is 38.38. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis.

More recent Luminex Corporation (NASDAQ:LMNX) news were brought out by Streetinsider.com, Prnewswire.com and Globenewswire.com. The first one has “Luminex Corp. (LMNX) Initiates Clinical Trials for VERIGENE II Gastrointestinal Assay” as a title and was brought out on June 13, 2018. The next is “Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay” on June 13, 2018. And last was brought out on June 20, 2018, called “Detailed Research: Economic Perspectives on MGM Growth Properties, Acacia Research, Luminex, Eastman …”.

Luminex Corporation (NASDAQ:LMNX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: